UCLH adopts CardioQ

Deltex Medical Group PLC
12 April 2007




                            Deltex Medical Group plc

 Major London Teaching Hospital makes CardioQ(TM) standard clinical practice for
                                 major surgery


12 April 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
UK's leading haemodynamic monitoring company, today announces that University
College London Hospital ('UCLH') has become the first hospital in the world to
make the use of Deltex Medical's CardioQ monitor standard clinical practice for
a wide range of major surgery.

UCLH has announced that the Enhanced Surgical Treatment and Recovery Programme
(ESTREP) will become standard clinical practice over the coming months, starting
this Spring with patients undergoing bowel surgery. UCLH expects the programme
to 'cut by more than half the recovery time for patients undergoing major
surgery across a wide range of specialties. This will in turn reduce the
millions of pounds spent by the NHS on keeping patients in hospital beds
unnecessarily.'

The key programme steps include the use of Deltex Medical's CardioQ oesophageal
Doppler monitor ('ODM') during surgery. Talking about the introduction of ODM,
the surgeon leading the project at UCLH, Mr Al Windsor, commented:

'The technology allowing for specialist anaesthetic care during the operation
was researched and developed at UCLH and I am delighted that it is to be
introduced as standard clinical practice.

'Using this 'home grown' technology coupled with the ESTREP package will save
the Trust both time and money, whilst providing the best possible care for our
patients.'

Deltex Medical's chief executive, Andy Hill, commented:

'UCLH has been intimately involved with the development of our products and it
is only fitting that it should lead the way and be the first hospital in the
world to formally implement the CardioQ as standard clinical practice for major
surgery.

'A growing number of hospitals in the UK and abroad plan to introduce similar
enhanced recovery or fast-track surgical programmes. ODM is the first and only
technology to enable doctors to haemodynamically optimise their patients during
surgery and we expect the CardioQ's implementation to be central to many of
these programmes.'


For further information, please contact:-

Deltex Medical Group plc          01243 774 837
Nigel Keen, Chairman              [e-mail]
Andy Hill, Chief Executive        [e-mail]
Ewan Phillips, Finance Director   [e-mail]

Gavin Anderson & Company          0207 554 1400
Deborah Walter                    [e-mail]
Robert Speed                      [e-mail]

Charles Stanley Securities        020 7149 6457
Russell Cook                      [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange